PMID- 29876671
OWN - NLM
STAT- MEDLINE
DCOM- 20190607
LR  - 20200306
IS  - 1433-8726 (Electronic)
IS  - 0724-4983 (Linking)
VI  - 37
IP  - 1
DP  - 2019 Jan
TI  - Validating the role of ABO blood type in risk of perioperative venous 
      thromboembolism after radical cystectomy.
PG  - 173-179
LID - 10.1007/s00345-018-2351-2 [doi]
AB  - PURPOSE: To validate the relationship between ABO blood type and risk of VTE 
      post-RC in a large retrospective database. METHODS: Patients with urothelial 
      bladder cancer (UBC) who underwent RC (intent-to-cure) for whom ABO blood type 
      was available between 2003 and 2015 were identified from our IRB-approved 
      database. VTE was defined as deep vein thrombosis (DVT) or pulmonary embolism 
      (PE) within 90 days of surgery. VTE prophylaxis consisted of immediate 
      postoperative Coumadin (2003-2009), unfractionated heparin (UFH) during 
      hospitalization (2009-2015), and UFH during hospitalization plus 4 weeks of 
      enoxaparin after discharge (2013-2015). Univariable and multivariable analyses of 
      the association of ABO blood type with postoperative, symptomatic VTE and 
      oncologic outcomes were performed. RESULTS: Of 1341 patients, 595 (44.4%) were 
      ABO type O and 746 (55.6%) were non-O (A, B and AB). 90 patients were diagnosed 
      with VTE within 90 days of surgery (6.7%) (43% DVT-only, 57% PE +/- DVT). On 
      multivariable analysis non-O blood type was associated with a nearly twofold 
      increased risk of VTE (OR = 1.94, 95% CI 1.215-3.098, p = 0.004). No difference 
      in recurrence-free survival or overall survival was seen between ABO groups. 
      CONCLUSION: Non-O blood type is an independent, non-modifiable risk factor for 
      postoperative VTE after RC. More comprehensive counseling and thromboprophylaxis 
      should be considered in this high-risk group.
FAU - Bhanvadia, Sumeet
AU  - Bhanvadia S
AD  - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, 
      USA.
FAU - Kazerouni, Kayvan
AU  - Kazerouni K
AD  - USC School of Medicine, Norris Comprehensive Cancer Center, USC Institute of 
      Urology, Los Angeles, CA, USA.
FAU - Bazargani, Soroush T
AU  - Bazargani ST
AD  - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, 
      USA.
FAU - Miranda, Gus
AU  - Miranda G
AD  - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, 
      USA.
FAU - Cai, Jie
AU  - Cai J
AD  - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, 
      USA.
FAU - Daneshmand, Siamak
AU  - Daneshmand S
AD  - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, 
      USA.
FAU - Djaladat, Hooman
AU  - Djaladat H
AUID- ORCID: 0000-0002-1984-3556
AD  - Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, 
      USA. djaladat@med.usc.edu.
AD  - University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, 
      CA, 90089, USA. djaladat@med.usc.edu.
LA  - eng
PT  - Journal Article
DEP - 20180606
PL  - Germany
TA  - World J Urol
JT  - World journal of urology
JID - 8307716
RN  - 0 (ABO Blood-Group System)
SB  - IM
MH  - *ABO Blood-Group System
MH  - Aged
MH  - Cystectomy/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Postoperative Complications/*blood/etiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Urinary Bladder Neoplasms/*blood/*surgery
MH  - Venous Thromboembolism/*blood/etiology
OTO - NOTNLM
OT  - Bladder
OT  - Cystectomy
OT  - MeSH
OT  - Thromboprophylaxis
OT  - Urothelial carcinoma
OT  - Venous thromboembolism
EDAT- 2018/06/08 06:00
MHDA- 2019/06/08 06:00
CRDT- 2018/06/08 06:00
PHST- 2018/01/10 00:00 [received]
PHST- 2018/05/25 00:00 [accepted]
PHST- 2018/06/08 06:00 [pubmed]
PHST- 2019/06/08 06:00 [medline]
PHST- 2018/06/08 06:00 [entrez]
AID - 10.1007/s00345-018-2351-2 [pii]
AID - 10.1007/s00345-018-2351-2 [doi]
PST - ppublish
SO  - World J Urol. 2019 Jan;37(1):173-179. doi: 10.1007/s00345-018-2351-2. Epub 2018 
      Jun 6.